Biogen Inc. (ETR:IDP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 15.31B |
| Revenue (ttm) | 9.35B |
| Net Income (ttm) | 1.58B |
| Shares Out | n/a |
| EPS (ttm) | 10.80 |
| PE Ratio | 9.71 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 263 |
| Average Volume | 350 |
| Open | 105.05 |
| Previous Close | 105.50 |
| Day's Range | 103.85 - 105.80 |
| 52-Week Range | 99.00 - 220.00 |
| Beta | 0.06 |
| RSI | 30.40 |
| Earnings Date | May 1, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
The European Commission (EC) on Tuesday approved Eisai Co., Ltd. (OTC: ESALY) and Biogen Inc.’s (NASDAQ: BIIB) amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) , The Commission said it gran...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh...
Biogen/ Eisai win EU approval for Alzheimer’s therapy
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Several exemptions exist among President Donald Trump ‘s broad tariffs , which were announced on Wednesday . The biopharma industry has historically been shielded from tariffs, including during Trump’...
Biogen downgraded to Hold at Argus on profit decline expectations
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an inves...
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today an...
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion that does not recommend Eli Lilly and Co's (NYSE: LLY) donanemab be granted marketing authori...
Biogen: Balancing Risks And Opportunities
Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is a Hold.
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Biogen plans new headquarters at Kendall Common
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a mul...
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally. The life sciences indu...
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stif...
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the effica...
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Decoding Biogen's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ: BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available opti...
How Is The Market Feeling About Biogen?
Biogen's (NYSE: BIIB) short percent of float has risen 3.1% since its last report. The company recently reported that it has 3.88 million shares sold short , which is 2.99% of all regular shares that...
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcar...